期刊
BRITISH JOURNAL OF CANCER
卷 112, 期 2, 页码 217-226出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/bjc.2014.476
关键词
melanoma; targeted therapy; beyond BRAF
类别
资金
- SPORE from the National Institutes of Health [P50 CA168536-01A1]
- [R01 CA161107-01]
In recent years, melanoma has become a poster-child for the development of oncogene-directed targeted therapies. This approach, which has been exemplified by the development of small-molecule BRAF inhibitors and the BRAF/MEK inhibitor combination for BRAF-mutant melanoma, has brought new hope to patients. Despite these successes, treatment failure seems near inevitable in the majority of cases-even in individuals treated with the BRAF/MEK inhibitor doublet. In the current review, we discuss the future of combination strategies for patients with BRAF-mutant melanoma as well as the emerging therapeutic options for patients with NRAS-mutant and BRAF/NRAS-wild-typemelanoma. We also outline some of the newest developments in the in-depth personalisation of therapy that should allow melanoma treatment to continue shaping the field precision cancer medicine.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据